Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Sleep Cycle, Audiocast, Q3'25

By Inderes10/24/2025, 7:30 AM
Sleep Cycle

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Erik Jivmark
00:00 - 08:34

As well. And thank you for joining us at Sleep Cycle's quarter three 2025 Interim Report Presentation. I'm Erik Jivmark. I'm the CEO of Sleep Cycle. I'm here together with our CFO and Head of Investor Relations, Elisabeth Hedman. And in this call, we will walk you through the key highlights from the quarter, our progress on the strategic initiatives, and also provide an update on our financials. Together, we will also address any questions you might have in the Q&A at the end. So we're Sleep Cycle, the world's leading sleep technology company. We have a mission to improve global health by helping people take control of their sleep. Everything we do aims to transform high-quality sleep into an accessible daily habit on a large scale. We're used and loved by millions and are available in more than 180 markets in app stores. And as part of many wearables today, we're proud to be the world's number one sleep app. We're helping people to build healthy sleep habits, something that is more needed than ever. But what sets us apart goes far beyond that. At the core of everything we do is our proprietary AI sound model. This technology not only powers the app millions of users rely on each night, but it also creates one of the world's richest health data streams. With the help of this, we're entering a new phase. We're entering a new phase. It's not a new strategy. It's a new execution model. For that strategy, we call it Powered by Sleep Cycle. During quarter three, we presented our Sleep SDK. Opening up access to this technology. Partners across wellness, healthcare, wearables, and beyond can now integrate our capabilities directly into their own platforms. To me, this is an extension of our successful partnership strategy. We're creating new high-margin revenue opportunities, reaching an audience outside our own app. Our strategy is clear: continue growing our consumer business while expanding the value of our platform. On one hand, that means strengthening user acquisition, engagement, and retention. On the other hand, we're building new monetization paths, especially around data technology and medtech with sleep apnea screening. This dual focus allows us to scale both our reach and our impact. Throughout the year. We've been very transparent about the fact that the sleep tracking segment has headwinds in the App Store. However, as you can see on the chart with data from Sensor Tower, we're performing relatively better than the entire health and fitness app segment. We're gaining market share in both downloads and revenue. Sleep apps are part of health and fitness. However, when we group together and compare ourselves with our direct competitors, our performance looks even better. We show resilience, and we achieve that by leading with product innovation and a stronger business acumen across the organization. Speaking of product development, in quarter three, we shipped a liquid glass design alongside iOS 16, making navigation clearer and highlighting premium value. We prepared the first AI Sleep Coach, planned to be released in quarter four to make the app more proactive, personalized, and habit-forming. Smart alarm refinements continue to improve perceived wake-up quality and are also helping our engagement. We also increased new sales prices by around 10% in key markets because revenue is recognized over 12 months. Reported lag. But the pricing supports our view in the long run. If we look at new sales for September, isolated ARPU was 296 SEK, but adjusted for FX, it was 318. We have continued to raise prices in October, so currently in the US, which is our largest market, new sales output is close to 500 SEK. Now in October, it's up 25% since July. This means that we are improving top-line performance over time, and it's also helping us in pricing the product correctly with future partners. And when it comes to partners, things are going very well. They continue to grow, up 55% year over year and 13% quarter over quarter. Partnerships now stand for 11% of total revenue. To me, partnerships are about reaching new customers without any additional acquisition cost. But it's also about taking control of our own destiny, relying less on storefronts, creating a more diversified and resilient revenue base, and a deeper presence in the wider health ecosystem. I am expecting the partnerships to continue to grow also in quarter four. But that's not all. During quarter three, we also took another major leap with our sleep SDK, allowing partners to integrate our world-leading AI sleep analysis into their products. It's contactless, it's real-time, and it's built on years of machine learning commercially. This opens up a new recurring licensing model. And it also accelerates how we scale our mission beyond our own app. During quarter three, the focus was to release the SDK for us to move from theoretical discussions with partners into more tangible dialogues. We are at the beginning of our journey, but I'm very excited about the possibilities ahead. But we don't stop with the SDK for other companies to license. We're also looking to use our own technology in new ways. So as part of this, we have sleep apnea, which affects over 950 million people worldwide, yet 80% remain undiagnosed. It exposes them to significantly higher risks of heart disease, stroke, and diabetes. Traditional diagnostics are costly and quite inaccessible. That's where Sleep Cycle comes in. We're using our proprietary audio-based AI, already trusted by millions nightly, to enable non-invasive smartphone-based apnea screening. No wearables, no cables, no clinic visits. AI-powered screening uses only the iPhone microphone. So medical-grade precision with consumer-grade simplicity. It's such a natural extension of our platform and it's aligned with our mission to improve global health. And importantly, it reflects the shift toward proactive, personalized healthcare. Our sleep apnea initiative represents one of the most significant growth opportunities for Sleep Cycle. This clinical study we launched in June is now about 20% complete, which marks an important step toward medical certification. As the study progresses, we're also working in parallel on documentation, audits, and commercial optimization. The goal is to be ready for submission to both the FDA and the European notified body toward the end of next year, 2026. Longer term, this initiative opens two strategic revenue paths: new consumer offerings within the app, and future healthtech licensing opportunities with partners in the healthcare ecosystem. So with that, I will hand over to Elisabeth who will walk us through the financial performance for the quarter.

Elisabeth Hedman
08:36 - 12:57

Thank you, Erik. Let's move on to the financials. The number of paying subscribers ended at 832,000, down 9% from last year, reflecting the softer development of these segments. But we have raised the prices, and the price adjustments we implemented during the quarter will gradually support output over time. Though the reported metric lags due to the recognition of revenue. And most of our subscriptions are 12 months. We continue testing new price points in different markets to improve the long-term value per customer. Net sales for the quarter amounted to 62 million, which is a decrease of 6.6% year over year, or 4.7% FX adjusted. FX-adjusted and EBIT for the quarter were 17 million SEK, with a margin of 27.3%. Let's take a look at the development in the number of paying subscribers and revenue. As I said, 132,000, mainly due to a lower intake of new customers and our focus on improving output and long-term value per user. Rather than pure volume growth, the retention among existing users remains stable, which shows the strength of the core product and user engagement. The net sales decreased by 6.6%, or 4.7% FX adjusted. FX adjusted, and the main drivers were lower. New customer sales continue despite FX pressure, while reported ARPU lags behind the impact of the recent price increases. Importantly, partnership revenue continues to grow strongly. It's up 55% year over year and now accounts for 11% of our total revenue. And this confirms that our diversification efforts are working and that partner demand for our brand and technology remains strong. If we move to profitability, you'll see that margins remain solid despite the softer top line. EBIT for the quarter came in at 7 million SEK, which corresponds to 26.3% to be compared with 31.3% a year ago. There have been no non-recurring items during this year, so despite the lower revenue top line, we do maintain the high margin for this quarter and the decrease in EBIT compared to last year is mainly explained by lower revenue and FX impact, while costs are well controlled. Distribution costs were lower due to reduced App Store commission as a result of fewer new sales. External costs were somewhat higher, linked to continued growth-related initiatives. Staff costs were stable, with a slight increase in headcount compared to last year, and the cash flow from operations was 5.5 million SEK. Liquidity remained strong at 114 million SEK at the end of the quarter, and we did capitalize 2.6 million SEK related to sleep apnea screening and Sleep SDK during the quarter. FX adjusted, and EBIT reached 52 million SEK. SEK, the number for last year, was impacted by non-recurring items related to reorganization, mainly within staff costs. So the EBIT margin for the period should be compared to 31.4% last year. And as I said for the quarter. External costs are slightly higher, reflecting growth-related activities, while depreciation decreased as the lease for the former Stockholm office is no longer in the base, and our cash generation continues to be strong. We had an operating cash flow for the full period of 42 million SEK, and we distributed 61 million SEK in dividends during Q2. We have capitalized 9.3 million SEK for the period, mainly related to the sleep apnea screening. Overall, this demonstrates a resilient business model with stable profitability and a healthy balance sheet. Now over to you, Erik, to summarize the quarter.

Erik Jivmark
12:57 - 14:32

Thank you, Elisabeth. So Q3 has been a very intense quarter. We are continuing our transformation. We are taking control of our own destiny by diversifying revenue streams and also expanding our core product into new areas such as AI coaching. We accomplish this while actively taking steps to protect our top line with price increases in key markets. Additionally, the Sleep SDK has been launched, allowing us to transition discussions from PowerPoint to reality. We're looking for pilot customers in the fourth quarter for our tech licensing initiative. Secondly, the sleep apnea study is progressing toward certification. We are now at a 20% completion rate in our clinical trials compared to other studies. We're moving fast and the team is doing a great job with this. And finally, earlier bets, such as our focus on partnerships, are paying off. We're up 55% year over year, and partnerships now constitute 11% of our revenue. That's why we will continue to focus and double down on it going forward. So together, these steps prepare the company for growth beyond the app stores. We have a clear strategy in place. We have a motivated and talented team. And together, we're building a more resilient Sleep Cycle for the future. And with that, we're opening up for any questions you might have.

Elisabeth Hedman
14:40 - 15:18

So we have a question from Johan Bergström, who asks if we will start reporting partnership revenue quarterly going forward. Yes, we started reporting this from Q2 and we plan to continue doing so. And we have a question here from Gustav. You say that you're still number one. Which competitors do you compare with in the US? If the US is your largest market, you are ranked 102, but you have several sleep tracking apps in the top 20 lists yielding higher rankings. What is the basis for your number one claim?

Erik Jivmark
15:18 - 15:45

Over time, we have become the largest sleep app. So I think the number you're looking at or referring to is probably a category ranking in the App Store. As I shared, the data from Sensor Tower, which is the official data that we refer to, shows that we capture both market share and revenue in the segment. So that is what supports the claim.

Elisabeth Hedman
15:47 - 16:06

Another question regarding the SDK program that is an exciting one, but I'm hesitant about user adoption due to the partner app requiring the user to have the app open while sleeping since you analyze sleep through sound. How do you tackle that? How many partners have onboarded into the SDK program?

Erik Jivmark
16:06 - 17:25

The SDK was launched approximately 20 days ago. In the discussions we have had, I see that we actually have quite a lot of partners where sound is something that would complement their offering and allow them to do things they cannot do today. It could also be things that are non-verbal. So it could be IoT-related stuff where sound is a natural part of how the consumer interacts with the product. But we also saw interest from companies today that would like to have the SDK as part of their app experience, where they would need the customer to have the app active during the night. But they see that there is an interest in doing so, given what they can give back to the customer in terms of data and experience. So I think, as I said previously in this quarter, I hope that we can sign some pilot customers and move from the discussions that we have into reality. So I hope we can talk more about that next time.

Elisabeth Hedman
17:26 - 17:43

Then we have a couple of questions regarding the dynamics between price increases and subscription development, what we can expect going forward and if the price increases could have affected the growth in subscriptions in Q3.

Erik Jivmark
17:44 - 18:49

I mean, the segment is what it is when it comes to growth. So that's why we want to be transparent about that. So what we do now with price is that we're making these changes in a very precise manner. So we're basically dividing the markets into different cohorts with different prices. And then we monitor that for a while and then we pick the one that optimizes revenue or sales the most. However, of course, we're also keeping an eye on how it impacts subscribers. So I think that answers that question. The other question was if the price increase could lead to growth already in quarter four. I think it's too early to say and not something I want to speculate on.

Elisabeth Hedman
18:51 - 19:11

Then we have a question regarding the Sleep Apnea study. If it proves successful and we move into commercialization, what would be considered a realistic scenario for its revenue contribution, both in terms of timing and how big a part of the business it could realistically become for Sleep Cycle?

Erik Jivmark
19:11 - 20:58

I mean, it's a very interesting question. What we're doing right now, in parallel with all the documentation and the clinical trials, is conducting tests with the customers. And we have to remember, we have a very big advantage in that we have millions of monthly active users. I think those users who today, for some reason, don't want to pay for a premium subscription for Sleep Cycle will be important in the future. They will come in very handy when we have an offer for sleep apnea screening. So once we're ready, we will not go out and try to find customers in B2C. We already have millions of customers using our product, so we will be instantly in a position where we can offer that to them, and that makes it very attractive to me. Likewise, what we will start doing during the next few quarters is to also advance our partnership focus into looking for partners that would like to utilize the SDK for Sleep Apnea. Once that is ready and approved. So we will have a dual focus here. It's hard to say what it would mean for Sleep Cycle in terms of exact monetary impact, etc. However, I'm of course very excited about the opportunity. And as I said on the call, this is a huge opportunity. It's close to a billion people that have this today. It's really hard for them to get the diagnosis and to get the help they need. I believe that this could absolutely be the biggest area in the future of Sleep Cycle. With us being medtech certified for sleep apnea screening.

Elisabeth Hedman
21:00 - 21:10

Then we have some questions from Jessica Grunwald at Redeye. Partnerships continue to perform strongly. Can you share insights on which partnerships are driving the most growth?

Erik Jivmark
21:11 - 21:33

We have some existing partners that we are growing, and we are also adding new partners on top of that. So, I can just say that when I look at the pipeline going forward and when I look at the partners that we have, that's why I say I feel very confident in that. I expect them to continue to grow also in this quarter.

Elisabeth Hedman
21:34 - 21:42

And the next question, what traction are you seeing with the Sleep SDK so far, and what types of partners are most engaged?

Erik Jivmark
21:44 - 22:10

Sorry. Okay. Now, I mean, right now we are discussing with partners in the wearables sector. We see a lot of traction with them because it's a very obvious fit, as they currently cannot offer sound and all the benefits that come with sound. So those are good discussions that we have. But then again, we have other IoT companies and also some apps that we're actively discussing with.

Elisabeth Hedman
22:14 - 22:15

Partnerships continue to perform strongly. That's it.

Erik Jivmark
22:15 - 22:29

Good. Thank you very much for your questions. Sorry for the delayed start due to technical problems, but I'm happy that you listened in and also for the good questions here towards the end. Thank you very much.

Elisabeth Hedman
22:29 - 22:30

Thank you very much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…